Accession Number
DB00019  (BTD00094, BIOD00094)
Biologic Classification
Protein Based Therapies
Haematopoietic growth factors

Pegfilgrastim is a modified form of filgrastim which has been PEGylated at the N terminus. It is a form of human G-CSF (Granulocyte colony stimulating factor) consisting of 175 residues and is produced from E. coli via bacterial fermentation. The first biosimilar was approved in June 2018 by Mylan NV as Fulphila (pegfilgrastim-jmdb).

Protein structure
Protein chemical formula
Protein average weight
18802.8 Da
> Pegfilgrastim sequence
Download FASTA Format
  • Granulocyte colony-stimulating factor pegfilgrastim
  • Peg-filgrastim
  • pegfilgrastim-cbqv
  • pegfilgrastim-jmdb
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FulphilaInjection6 mg/0.6mLSubcutaneousMylan Institutional LLC2018-07-09Not applicableUs
LapelgaSolution6 mgSubcutaneousApotex CorporationNot applicableNot applicableCanada
NeulastaKit6 mg/0.6mLSubcutaneousAmgen2002-04-01Not applicableUs
NeulastaSolution10 mgSubcutaneousAmgen2004-03-12Not applicableCanada
NeulastaInjection6 mg/0.6mLSubcutaneousPhysicians Total Care, Inc.2006-02-232011-12-31Us
NeulastaInjection6 mg/0.6mLSubcutaneousAmgen2002-04-01Not applicableUs
UdenycaInjection, solution6 mg/0.6mLSubcutaneousCoherus BioSciences Inc2018-11-02Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
NeupopegPegfilgrastim (6 mg)Injection, solutionSubcutaneousDompé Biotec S.P.A.2002-08-222008-12-22Eu
NeupopegPegfilgrastim (6 mg)Injection, solutionSubcutaneousDompé Biotec S.P.A.2002-08-222008-12-22Eu
NeupopegPegfilgrastim (6 mg)Injection, solutionSubcutaneousDompé Biotec S.P.A.2002-08-222008-12-22Eu
CAS number



Pegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure.

Associated Conditions

Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim.

Mechanism of action

Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase.

AGranulocyte colony-stimulating factor receptor
UNeutrophil elastaseNot AvailableHuman

Pegfilgrastim has an absolute bioavailability of 60-70% [1]. It is slowly absorbed following subcutaneous administration with a time to peak concentration of about 1-2 days. It is thought that the lymphatic system plays a large role in absorption due to the large size of the protein and attached PEG group.

Volume of distribution

Pegfilgrastim appears to have a volume of distribution of approximately 170L [2].

Protein binding
Not Available

Pegfilgrastim is thought to be broken down into amino acids similarly to endogenous proteins.

Route of elimination

Pegfilgrastim clearance by renal filtration is negligible due to the large hydrodynamic radius afforded by the PEG group [1]. The primary route of elimination involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells as part of a negative feedback system which also processes endogenous G-CSF. While hepatic clearance has not been well characterized for pegfilgrastim, its non-PEGylated precursor Filgrastim is known to be unaffected by changes in hepatic clearance. During chemotherapy-induced neutropenia, the clearance of pegfilgrastim is significantly reduced and the concentration of pegfilgrastim is sustained until onset of neutrophil recovery.

Half life

Approximately 15-80 h [Label].


Clearance is not well characterized as pegfilgrastim is primarily cleared by granulocytes as part of a negative feedback system [1]. Clearance increases as the number of granulocytes increases.


The most common adverse events experienced included bone pain and extremity pain [Label]. Rarely, leukocytosis was observed after pegfilgrastim administration. As a protein, pegfilgrastim has the potential for immunogenicity but this was observed in less than 1% of studied patients.

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
CyclophosphamideThe risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.
PegloticaseThe therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Pegloticase.
TopotecanThe risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.
Food Interactions
Not Available


General References
  1. Yang BB, Kido A: Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. [PubMed:21456630]
  2. Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R, Baczkowski M, Kothekar MA, Micales CE, Barve A, Ranganna GM, Pennella EJ: A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol. 2018 Jun;144(6):1087-1095. doi: 10.1007/s00432-018-2643-3. Epub 2018 Apr 18. [PubMed:29671069]
External Links
PubChem Substance
Therapeutic Targets Database
RxList Drug Page Drug Page
ATC Codes
L03AA13 — Pegfilgrastim
AHFS Codes
  • 20:16.00 — Hematopoietic Agents
FDA label
Download (920 KB)

Clinical Trials

Clinical Trials
0Not Yet RecruitingTreatmentMetastatic Pheochromocytoma / Relapsed Neuroblastoma1
1Active Not RecruitingOtherHealthy Volunteers2
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Tumors, Solid1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1Active Not RecruitingTreatmentProstate Cancer1
1CompletedNot AvailableBioequivalence1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableImmunity, Humoral1
1CompletedNot AvailableNeutropenias1
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedOtherHealthy Volunteers1
1CompletedOtherHealthy Volunteers / Neutropenias1
1CompletedPreventionCancer, Breast1
1CompletedTreatmentAplastic Anaemia (AA)1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancer, Advanced / Metastatic Cancers1
1CompletedTreatmentCrohn's Disease (CD)1
1CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1CompletedTreatmentEndometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1CompletedTreatmentFallopian Tube Carcinoma / Infectious Disorder / Neutropenias / Ovarian Carcinosarcoma / Primary Peritoneal Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
1CompletedTreatmentPharmacology, Clinical1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRecurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentSclerosis, Progressive Systemic1
1RecruitingTreatmentAmyloidosis / Multiple Myeloma (MM)1
1RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Ependymoma / Anaplastic Ganglioglioma / Anaplastic Meningioma / Anaplastic Oligodendroglioma (AO) / Atypical Teratoid/Rhabdoid Tumor / Brain Cancer / Central Nervous System Neoplasms / Choroid Plexus Carcinoma / CNS Embryonal Tumor With Rhabdoid Features / CNS Tumors / Embryonal Tumor of CNS / Embryonal Tumor With Multilayered Rosettes (ETMR) / Embryonal Tumor, NOS / Ependymoma, NOS, WHO Grade II / Ependymoma, NOS, WHO Grade III / Ependymoma, Recurrent / Ependymoma, RELA Fusion Positive / Ependymomas / Ganglioneuroblastoma of Central Nervous System / Glioblastoma, IDH-mutant / Glioblastoma, IDH-wildtype / Glioblastomas / Glioma, Diffuse Midline, H3K27M-mutant / Glioma, High Grade / Glioma, Malignant / Glioma, Recurrent High Grade / Glioma, Recurrent Malignant / Gliomas / Medulloblastoma, Chromosome 9q Loss / Medulloblastoma, G3/G4 / Medulloblastoma, Group 3 / Medulloblastoma, Group 4 / Medulloblastoma, Non-WNT Non-SHH, NOS / Medulloblastoma, Non-WNT/Non-SHH / Medulloblastoma, PTCH1 Mutation / Medulloblastoma, SHH-activated and TP53 Mutant / Medulloblastoma, SHH-activated and TP53 Wildtype / Medulloblastoma, WNT-activated / Medulloblastoma; Unspecified Site / Medulloblastomas / Medulloepithelioma / Neoplasms / Neoplasms, Brain / Neoplasms, Neuroepithelial / Neuroblastoma. CNS / Neuroepithelial Tumor / Neuroepithelial Tumor, High Grade / Papillary Tumor of the Pineal Region (High-grade Only) / Pediatric Brain Tumor / Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only) / Pinealoblastoma / Pleomorphic Xanthoastrocytoma, Anaplastic / Primitive Neuroectodermal Tumor / Recurrent Medulloblastoma / Refractory Brain Tumor1
1RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / CD20 Negative / CD20 Positive / HIV Positivity / Human Immunodeficiency Virus Positive / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentCancer, Breast / Neoplasms Metastasis / Neoplasms, Colorectal1
1RecruitingTreatmentChildhood Solid Tumors1
1RecruitingTreatmentCoronary Artery Atherosclerosis1
1RecruitingTreatmentHodgkins Disease (HD) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral1
1RecruitingTreatmentMalignancies / Neoplasms / Neuroendocrine Tumors / Tumors1
1RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1RecruitingTreatmentPlasma Cell Myeloma1
1TerminatedTreatmentAdult Solid Neoplasm / Colorectal Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Recurrent Breast Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Melanoma of the Skin / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Pancreatic Carcinoma / Renal Cell Carcinoma Recurrent / Solid Neoplasms / Stage IV Breast Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Renal Cell Cancer / Stage IV Skin Melanoma / Stage IVA Colorectal Cancer / Stage IVA Pancreatic Cancer / Stage IVB Colorectal Cancer / Stage IVB Pancreatic Cancer1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentLung Cancer Metastatic / Sarcoma, Osteogenic1
1Unknown StatusTreatmentNeutropenias1
1WithdrawnTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma / Lymphoma, Hodgkins1
1, 2Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentAcute Myeloblastic Leukemia1
1, 2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentInfertility, Female1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Smith-Magenis Syndrome1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas1
1, 2CompletedTreatmentLeukemias / Richter's Transformation1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentLymphoma, Hodgkins1
1, 2CompletedTreatmentMalignant Lymphomas / Non Hodgkin Lymphoma (NHL)1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma1
1, 2Not Yet RecruitingTreatmentAutoimmune Diseases / Diabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
1, 2RecruitingTreatmentCancer of the Ovary / Lung Cancer Small Cell Lung Cancer (SCLC)1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Other Diseases of Blood and Blood-Forming Organs1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
1, 2RecruitingTreatmentSarcomas1
1, 2TerminatedTreatmentAggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Follicular Lymphoma Grade III (FL III°) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL), Blastoid Variant1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2TerminatedTreatmentInfertility, Female1
1, 2TerminatedTreatmentMale Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2TerminatedTreatmentPain NOS / Prostate Cancer1
1, 2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Cancer of the Ovary / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
1, 2Unknown StatusTreatmentCritical Limb Ischemia (CLI) / Diabetic Foot / Ulcer, Leg1
2Active Not RecruitingOtherCancer, Breast / Locally Advanced Malignant Neoplasm1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Adenosquamous Lung Carcinoma / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Large Cell Lung Carcinoma / Minimally Invasive Lung Adenocarcinoma / Squamous Cell Carcinoma of Lung / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2Active Not RecruitingTreatmentCancer, Breast2
2Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
2Active Not RecruitingTreatmentHER2-Negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingTreatmentHER2-Positive Early Stage Breast Cancer1
2Active Not RecruitingTreatmentLeukemias2
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2CompletedNot AvailableCancer, Breast1
2CompletedPreventionMultiple Myeloma (MM)1
2CompletedPreventionNeutropenias / Sarcomas1
2CompletedPreventionUnresectable Locally Advanced NSCLC1
2CompletedSupportive CareColorectal Cancers / Malignant Neoplasm of Colon / Rectal Carcinoma1
2CompletedSupportive CareLung Cancers1
2CompletedSupportive CareMalignant Lymphomas / Neutropenias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Small Cell Carcinoma / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage III Cervical Cancer / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Cancer Recurrent / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAnemias / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Neutropenias1
2CompletedTreatmentAplastic Anaemia (AA) / Myelodysplastic Syndrome1
2CompletedTreatmentBladder Cancers / Muscle-invasive Bladder Cancer1
2CompletedTreatmentBone Pain in Stage I - III Breast Cancer1
2CompletedTreatmentBrain and Central Nervous System Tumors / Cancer of the Ovary / Extragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
2CompletedTreatmentCancer of Head and Neck / Cancer of the Ovary / Colorectal Cancers / Esophageal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Stomach / Prostate Cancer1
2CompletedTreatmentCancer of the Ovary / Cancer, Breast / Lung Cancers1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer of the Ovary / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Breast5
2CompletedTreatmentCancer, Breast / Fevers / Neutropenias1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Breast / Neutropenias1
2CompletedTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer1
2CompletedTreatmentCarcinoma of Head/Neck / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentChemotherapy Induced Neutropenia1
2CompletedTreatmentContiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDiamond Blackfan Anemia1
2CompletedTreatmentDistal Urethral Cancer / Metastatic Bladder Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer1
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Rhabdomyosarcomas1
2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
2CompletedTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
2CompletedTreatmentFemale Breast Cancer1
2CompletedTreatmentHematological Neoplasms / Tumors1
2CompletedTreatmentHematology / Lymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Oncology1
2CompletedTreatmentHodgkins Disease (HD) / Leukaemia, Lymphoblastic / Multiple Myeloma (MM) / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLeukemia, Myelocytic, Acute1
2CompletedTreatmentLeukemias / Malignant Lymphomas2
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentMale Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
2CompletedTreatmentMalignant Lymphomas8
2CompletedTreatmentMalignant Lymphomas / Plasma Cell Myeloma1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Renal Cell Carcinoma / Renal Cell Carcinoma With Sarcomatoid Features1
2CompletedTreatmentMultiple Myeloma (MM)2
2CompletedTreatmentMyeloid Leukemias1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Ovarian1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)4
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Corpus Leiomyosarcoma1
2CompletedTreatmentTransitional Cell Carcinoma1
2Enrolling by InvitationTreatmentChronic Chagasic Myocarditis1
2Not Yet RecruitingTreatmentLocally Advanced Breast Cancer (LABC)1
2RecruitingPreventionCancer, Breast / Neutropenia, Febrile / Neutropenias1
2RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukemia With BCR-ABL1 / Philadelphia Chromosome Positive / Refractory Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitt Leukemia/Lymphoma / Hematopoietic/Lymphoid Cancer / Lymphoma, Lymphoblastic1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAlcoholic Hepatitis (AH)1
2RecruitingTreatmentChemotherapy Induced Neutropenia1
2RecruitingTreatmentEarly Stage Breast Cancer1
2RecruitingTreatmentHer2-Positive Breast Cancer / Operable Breast Cancer1
2RecruitingTreatmentInfiltrating Bladder Urothelial Carcinoma / Stage II Bladder Urothelial Carcinoma / Stage III Bladder Urothelial Carcinoma1
2RecruitingTreatmentLymphoma, Hodgkins1
2RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN) / Squamous Cell Carcinoma, Head And Neck1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2SuspendedTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2TerminatedTreatmentBone Cancer / Ewing's Sarcoma (ES)1
2TerminatedTreatmentBrain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas / Thrombocytopenias1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast / Tumors, Breast1
2TerminatedTreatmentCancer of the Ovary1
2TerminatedTreatmentHead and Neck Carcinoma1
2TerminatedTreatmentHematologic Diseases1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMelanoma Metastatic1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentPreviously Treated Non Small Cell Lung Cancer1
2TerminatedTreatmentSolid Malignancies1
2Unknown StatusTreatmentBortezomib / Cyclophosphamide / Dexamethasone / Granulocyte Colony-Stimulating Factor / Plasma Cell Myeloma1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2Unknown StatusTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Unknown StatusTreatmentLeukemias1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Unknown StatusTreatmentSolid Malignancies1
2WithdrawnTreatmentAnterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2, 3CompletedPreventionChemotherapy Induced Neutropenia1
2, 3CompletedSupportive CareChemotherapy Induced Neutropenia1
2, 3CompletedTreatmentChronic Ischaemic Heart Failure1
2, 3CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2, 3CompletedTreatmentLiver Cirrhosis1
2, 3RecruitingSupportive CareChemotherapy Induced Neutropenia2
2, 3RecruitingTreatmentCastrate Resistant Prostate Cancer (CRPC)1
2, 3TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic, Acute / Smith-Magenis Syndrome1
2, 3Unknown StatusTreatmentDe Novo Akute Myeloid Leukemia (AML) / Refractory Anemia With Excess of Blasts in Transformation / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)1
3Active Not RecruitingTreatmentCancer, Breast3
3Active Not RecruitingTreatmentCancer, Breast / Neutropenias1
3Active Not RecruitingTreatmentEndometrial Cancers / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
3Active Not RecruitingTreatmentLarge B Cell Lymphoma1
3Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3Active Not RecruitingTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
3Active Not RecruitingTreatmentMalignant Lymphomas2
3Active Not RecruitingTreatmentMyelokathexis / Neutropenias / Warts / WHIMS1
3Active Not RecruitingTreatmentStage I Uterine Sarcoma / Stage I Uterine Sarcoma AJCC v7 / Uterine Corpus Leiomyosarcoma1
3Active Not RecruitingTreatmentTriple Negative Breast Neoplasms1
3CompletedPreventionMalignant Neoplasm of Female Breast1
3CompletedSupportive CareBreast Cancer Patients Treated With Myelosuppressive Chemotherapy / Neutropenic Complications1
3CompletedSupportive CareCancer, Breast / Chemotherapy Induced Neutropenia1
3CompletedSupportive CareChemotherapy Induced Neutropenia1
3CompletedSupportive CareColorectal Cancers / Fevers / Locally Advanced / Malignancies / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Neutropenias / Rectal Carcinoma1
3CompletedTreatmentAggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia1
3CompletedTreatmentCancer, Breast4
3CompletedTreatmentChemotherapy Induced Neutropenia1
3CompletedTreatmentChemotherapy-Induced Febrile Neutropenia / Neoplasms, Breast1
3CompletedTreatmentElderly Patients (>65 Years) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer1
3CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3CompletedTreatmentWomen With Recurrent Implantation Failure (Three Previous IVF Attempts Failed and at Least 8 Good Embryos Replaced1
3Not Yet RecruitingPreventionMalignant Lymphomas / Neutropenias1
3RecruitingPreventionCancer, Breast1
3RecruitingTreatmentBreastcancer / Neutropenias1
3RecruitingTreatmentCancer, Breast / Neutropenias1
3RecruitingTreatmentChildhood Teratoma / Choriocarcinoma / Extragonadal Seminoma / Germ Cell Tumors / Germinoma / Malignant Germ Cell Neoplasm / Mixed Germ Cell Tumor / Non-seminomatous Germ Cell Tumors / Seminoma / Teratoma / Yolk Sac Tumor1
3RecruitingTreatmentGerm Cell Tumors1
3RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
3TerminatedPreventionCancer treatment / Cancer, Breast / Neutropenia, Febrile1
3TerminatedTreatmentAplastic Anaemia (AA)1
3TerminatedTreatmentLung Cancers1
3TerminatedTreatmentRecurrent Uterine Corpus Sarcoma / Stage IIIA Uterine Sarcoma / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma / Uterine Corpus Leiomyosarcoma1
3Unknown StatusTreatmentCancer, Breast2
3Unknown StatusTreatmentIPI≥2 / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Unknown StatusTreatmentMantle Cell Lymphoma (MCL)1
4CompletedPreventionCancer of the Ovary / Cancer, Breast / Lung Cancers / Neutropenias / Non-Hodgkin's Lymphoma (NHL)1
4CompletedPreventionCancer, Breast2
4CompletedPreventionMalignant Lymphomas1
4CompletedPreventionMalignant Solid Tumours1
4CompletedSupportive CareCancer, Breast1
4CompletedTreatmentAcute Myeloblastic Leukemia / Myelodysplastic Syndrome1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia2
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
4CompletedTreatmentRecurrent Abortion1
4RecruitingTreatmentCancer, Breast1
4RecruitingTreatmentHepatic Failure / Severe alcoholic liver disease / Viral Hepatitis B1
4Unknown StatusSupportive CareCancer, Breast / Neutropenias1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia1
4Unknown StatusTreatmentLeukemia Acute Myeloid Leukemia (AML)1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Lung Cancers1
Not AvailableActive Not RecruitingDiagnosticSarcomas1
Not AvailableCompletedPreventionSarcomas1
Not AvailableCompletedTreatmentCancer, Breast2
Not AvailableCompletedTreatmentCirrhosis, Decompensated1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableCompletedTreatmentMyocardial Infarction1
Not AvailableCompletedTreatmentSevere Alcoholic Hepatitis1
Not AvailableRecruitingTreatmentMalignant Lymphomas1
Not AvailableRecruitingTreatmentMetastatic Pheochromocytoma / Relapsed Neuroblastoma1
Not AvailableTerminatedOtherLeukemia Acute Myeloid Leukemia (AML)1
Not AvailableTerminatedTreatmentMalignancies, Hematologic1
Not AvailableTerminatedTreatmentNon Hodgkin Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentCancer, Breast1


Not Available
  • Amgen Inc.
  • Physicians Total Care Inc.
Dosage forms
SolutionSubcutaneous6 mg
InjectionSubcutaneous6 mg/0.6mL
KitSubcutaneous6 mg/0.6mL
SolutionSubcutaneous10 mg
Injection, solutionSubcutaneous6 mg
Injection, solutionSubcutaneous6 mg/0.6mL
Unit descriptionCostUnit
Neulasta 6 mg/0.6 ml syringe4102.37USD syringe
Neulasta 6 mg/0.6ml Solution 0.6ml Syringe4026.05USD syringe
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)


Experimental Properties
melting point (°C)60 °CLuo, P., Protein Science 11:1218-1226 (2002)
hydrophobicity0.209Not Available
isoelectric point5.65Not Available


Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available


Pharmacological action
General Function
Receptor activity
Specific Function
Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differientation and survival of cells along the neutroph...
Gene Name
Uniprot ID
Uniprot Name
Granulocyte colony-stimulating factor receptor
Molecular Weight
92155.615 Da
  1. Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25. [PubMed:17001306]
  2. Elsasser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G: The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene. 2003 Aug 28;22(36):5646-57. [PubMed:12944913]
  3. Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18. [PubMed:17127322]
  4. Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20. [PubMed:16033816]
  5. Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients]. Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8. [PubMed:15949269]
  6. Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA: Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8. [PubMed:15082029]
Pharmacological action
General Function
Serine-type endopeptidase activity
Specific Function
Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis.
Gene Name
Uniprot ID
Uniprot Name
Neutrophil elastase
Molecular Weight
28517.81 Da
  1. Carter CR, Whitmore KM, Thorpe R: The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol. 2004 Mar;75(3):515-22. Epub 2003 Dec 4. [PubMed:14657210]
  2. Jian MY, Koizumi T, Tsushima K, Fujimoto K, Kubo K: Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046) on acid-induced lung injury in rats. Inflammation. 2004 Dec;28(6):327-36. [PubMed:16245075]
  3. Pelus LM, Bian H, King AG, Fukuda S: Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood. 2004 Jan 1;103(1):110-9. Epub 2003 Sep 4. [PubMed:12958067]
  4. Druhan LJ, Ai J, Massullo P, Kindwall-Keller T, Ranalli MA, Avalos BR: Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood. 2005 Jan 15;105(2):584-91. Epub 2004 Sep 7. [PubMed:15353486]
  5. Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ: Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007 Aug 15;110(4):1317-25. Epub 2007 May 2. [PubMed:17475913]

Drug created on June 13, 2005 07:24 / Updated on November 18, 2018 04:38